ChemoCentryx, Inc. (CCXI) Hit 52-Week High

March 21, 2018 - By Michael Pereira

Investors sentiment decreased to 1.14 in Q3 2017. Its down 0.26, from 1.4 in 2017Q2. It dived, as 12 investors sold ChemoCentryx, Inc. shares while 23 reduced holdings. 12 funds opened positions while 28 raised stakes. 23.75 million shares or 2.21% less from 24.29 million shares in 2017Q2 were reported.
Invesco Limited invested 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Tiaa Cref Inv Mgmt Limited Liability Co, New York-based fund reported 110,008 shares. Geode Cap Ltd Llc reported 241,907 shares stake. Northern Tru has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Macquarie Group Ltd accumulated 0% or 8,631 shares. California State Teachers Retirement reported 38,082 shares stake. 54,178 were accumulated by Banque Pictet And Cie. Royal Bank & Trust Of Canada invested in 2,132 shares or 0% of the stock. Los Angeles Capital Management And Equity Rech Inc invested 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Iguana Healthcare Mgmt Ltd owns 275,000 shares. 29,111 were accumulated by Proshare Advisors Ltd Liability Com. Credit Suisse Ag has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Paw Capital has 1.24% invested in ChemoCentryx, Inc. (NASDAQ:CCXI). State Street Corp reported 0% stake. Schwab Charles owns 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 35,200 shares.

The stock of ChemoCentryx, Inc. (NASDAQ:CCXI) hit a new 52-week high and has $15.92 target or 7.00 % above today’s $14.88 share price. The 6 months bullish chart indicates low risk for the $727.71 million company. The 1-year high was reported on Mar, 21 by If the $15.92 price target is reached, the company will be worth $50.94 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 4.31% or $0.62 during the last trading session, reaching $14.88. About 164,519 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 60.64% since March 21, 2017 and is uptrending. It has outperformed by 43.94% the S&P500.

Analysts await ChemoCentryx, Inc. (NASDAQ:CCXI) to report earnings on May, 9. They expect $-0.19 earnings per share, down 58.33 % or $0.07 from last year’s $-0.12 per share. After $0.80 actual earnings per share reported by ChemoCentryx, Inc. for the previous quarter, Wall Street now forecasts -123.75 % negative EPS growth.

ChemoCentryx, Inc. (NASDAQ:CCXI) Ratings Coverage

Among 4 analysts covering ChemoCentryx (NASDAQ:CCXI), 2 have Buy rating, 1 Sell and 1 Hold. Therefore 50% are positive. ChemoCentryx has $16 highest and $1300 lowest target. $14.50’s average target is -2.55% below currents $14.88 stock price. ChemoCentryx had 6 analyst reports since September 3, 2015 according to SRatingsIntel. JP Morgan maintained ChemoCentryx, Inc. (NASDAQ:CCXI) on Tuesday, March 13 with “Overweight” rating. The stock has “Mkt Outperform” rating by JMP Securities on Tuesday, February 21. The stock of ChemoCentryx, Inc. (NASDAQ:CCXI) earned “Buy” rating by JMP Securities on Thursday, August 10. The firm has “Sell” rating by Zacks given on Thursday, September 3. The firm has “Sell” rating given on Monday, September 21 by Zacks. The stock of ChemoCentryx, Inc. (NASDAQ:CCXI) earned “Hold” rating by Cowen & Co on Tuesday, August 8.

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company has market cap of $727.71 million. The Company’s lead drug candidate is Avacopan , an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). It has a 41.32 P/E ratio. The firm also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe CrohnÂ’s diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: